[HTML][HTML] Signaling pathways in obesity: mechanisms and therapeutic interventions

X Wen, B Zhang, B Wu, H Xiao, Z Li, R Li… - Signal transduction and …, 2022 - nature.com
Obesity is a complex, chronic disease and global public health challenge. Characterized by
excessive fat accumulation in the body, obesity sharply increases the risk of several …

[HTML][HTML] Long-term efficacy and safety of anti-obesity treatment: where do we stand?

YJ Tak, SY Lee - Current obesity reports, 2021 - Springer
Abstract Purpose of Review As a chronic and relapsing disease, obesity impairs metabolism
and causes cardiovascular diseases. Although behavioral modification is important for the …

[HTML][HTML] RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020Table. No title available.

R Chawla, SV Madhu, BM Makkar… - Indian journal of …, 2020 - journals.lww.com
Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.

[HTML][HTML] Anti-obesity drugs: long-term efficacy and safety: an updated review

YJ Tak, SY Lee - The world journal of men's health, 2021 - ncbi.nlm.nih.gov
As a chronic and relapsing disease, obesity negatively impacts the health of men to a
greater extent than that of women, with a higher risk of cardiovascular disease. Since …

Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs

AK Singh, R Singh - Expert review of clinical pharmacology, 2020 - Taylor & Francis
Introduction: Obesity poses a significant increase in morbidity and mortality and thus five anti-
obesity drugs have been approved currently by US FDA. Several phase 3 trials have shown …

Interventions for reversing prediabetes: a systematic review and meta-analysis

KI Galaviz, K Suvada, R Merchant… - American journal of …, 2022 - Elsevier
Introduction Several interventions have been found to be effective for reversing prediabetes
in adults. This systematic review and meta-analysis aims to compare the effectiveness of …

Diabetic cardiomyopathy: prevalence, determinants and potential treatments

GS Gulsin, L Athithan… - Therapeutic advances in …, 2019 - journals.sagepub.com
The prevalence of type 2 diabetes (T2D) has reached a pandemic scale. These patients are
at a substantially elevated risk of developing cardiovascular disease, with heart failure (HF) …

[HTML][HTML] Pharmacological approaches to the prevention of type 2 diabetes mellitus

P Majety, FA Lozada Orquera, D Edem… - Frontiers in …, 2023 - frontiersin.org
About 1 in 10 adults worldwide are estimated to have diabetes mellitus. They are at risk of
developing life-threatening complications resulting in reduced quality of life, increased …

Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF

SE Inzucchi, KF Docherty, L Køber… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of
cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of …

[HTML][HTML] Pharmacological support for the treatment of obesity—present and future

M Kosmalski, K Deska, B Bąk, M Różycka-Kosmalska… - Healthcare, 2023 - mdpi.com
Obesity is a growing civilization problem, associated with a number of negative health
consequences affecting almost all tissues and organs. Currently, obesity treatment includes …